666747-06-4

Basic information

• Product Name: 2,4-Dibromobenzyl Alcohol
• Synonyms: 2,4-Dibromobenzyl alcohol;2,4-dibromoBenzenemethanol
• CAS NO: 666747-06-4
• Molecular Formula: C₇H₆Br₂O
• Molecular Weight: 265.93
• Product Categories: Alcohols;Bromine Compounds
• Mol File: 666747-06-4.mol

Chemical Properties

• Melting Point: 80.0 to 84.0 °C
• Boiling Point: 322.1ºC at 760 mmHg
• Flash Point: 148.6ºC
• Appearance: /Solid
• Density: 1.960
• Vapor Pressure: 0.000117mmHg at 25°C
• Refractive Index: 1.627
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.74±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 2,4-Dibromobenzyl Alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dibromobenzyl Alcohol(666747-06-4)
• EPA Substance Registry System: 2,4-Dibromobenzyl Alcohol(666747-06-4)

Safety Data

• Hazardous Substances Data: 666747-06-4(Hazardous Substances Data)

Usage

Uses

Used in Proteomics Research:
2,4-Dibromobenzyl Alcohol is used as a halogenated compound for proteomics research, where it aids in the identification and analysis of proteins and their functions within biological systems.
Used in Pharmaceutical Industry:
2,4-Dibromobenzyl Alcohol is used as an intermediate in the synthesis of pharmaceutical compounds, contributing to the development of new drugs and therapeutic agents. Its unique structure and properties make it a valuable component in the creation of innovative medications.

InChI:InChI=1/C7H6Br2O/c8-6-2-1-5(4-10)7(9)3-6/h1-3,10H,4H2

Upstream product

• 31543-75-6 2,4-dibromotoluene 
• 54335-33-0 methyl 2,4-dibromobenzoate 
• 611-00-7 2,4-dibromobenzoic acid 
• 78222-69-2 2,4-dibromobenzonitrile 
• 615-57-6 2,4-dibromo-aniline 
• 5629-98-1 2,4-dibromobenzaldehyde 
• 64382-92-9 2,4-dibromo-1-(bromomethyl)benzene 
• 858841-41-5 2,4-dibromo-benzyl chloride 

Downstream Products

• 611-00-7 2,4-dibromobenzoic acid 
• 858841-41-5 2,4-dibromo-benzyl chloride 
• 98434-44-7 (2,4-dibromophenyl)acetic acid 
• 943906-71-6 2,4-dibromophenethyl alcohol 
• 66246-16-0 2-(2,4-dibromophenyl)acetonitrile 
• 92104-02-4 6-bromo-2-phenylbenzofuran 
• 64382-92-9 2,4-dibromo-1-(bromomethyl)benzene 

Relevant articles and documents

Synthetic method 2 and 4 - dibromobenzyl alcohol

The invention provides 2-4 - dibromobenzyl alcohol synthesis method, and the specific steps are as follows: S1, 2, 4 - dibromotoluene is brominated 2 and 4 - dibromobenzyl bromide in a radical initiator. S2 represents 2, 4 - dibromobenzylacetate in acetat

Strategy for Overcoming Full Reversibility of Intermolecular Radical Addition to Aldehydes: Tandem C-H and C-O Bonds Cleaving Cyclization of (Phenoxymethyl)arenes with Carbonyls to Benzofurans

An intermolecular addition of carbon radicals enabled by a cascade radical coupling strategy is developed. It includes an intermolecular alkyl radical addition to a carbonyl group followed by an intramolecular alkoxy radical addition to haloarenes and produces substituted benzofurans in high yields. The radical nature of this reaction is explored by radical trapping experiments and EPR analysis. The mechanism is investigated by KIE experiments and control experiments. This method could provide rapid and practical access to the key intermediate of TAM-16, a safe and potent antibacterial agent for treating tuberculosis, and, therefore, is of great importance for organic synthesis and the pharmaceutical industry.

IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.

Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation

A series of 2-aminoalkylethers prepared as potential antiarrhythmic agents is described. The present compounds are mixed sodium and potassium ion channel blockers and exhibit antiarrhythmic activity in a rat model of ischemia-induced arrhythmias. Structure-activity studies led to the identification of three compounds 5, 18, and 26, which were selected based on their particular in vivo electrophysiological properties, for studies in two canine atrial fibrillation (AF) models. The three compounds converted AF in both models, but only compound 26 was shown to be orally bioavailable. Resolution of the racemate 26 into its corresponding enantiomers 40 and 41 and subsequent biological testing of these enantiomers led to the selection of (1S,2S)-1-(1-naphthalenethoxy)-2-(3- ketopyrrolidinyl)cyclohexane monohydrochloride (41) as a potential atrial selective antiarrhythmic candidate for further development.